CTOs on the Move

Vaxcyte

www.vaxcyte.com

 
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte`s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and the XpressCFᵀᴹ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company`s system for producing difficult-to-make proteins and antigens is intended ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.vaxcyte.com
  • 825 Industrial Road Suite 300
    San Carlos, CA USA 94070
  • Phone: 650.837.0111

Executives

Name Title Contact Details

Similar Companies

Vanessa

Vanessa is a Rockland, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arcellx

Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx`s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx`s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration. Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, expected to enter the clinic in the second half of 2022.

Go Partners Heath Care Solutions

Go Partners Heath Care Solutions is a Jefferson City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Turn Biotechnologies

Turn Biotechnologies develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. We are focused on reprogramming the epigenome – a network of chemical compounds and proteins that control cell functions by influencing which genes are active – to restore capabilities that are often lost with age.

EMD Chemicals

EMD Chemicals Inc. is a Gibbstown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.